Latest News and Press Releases

CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

Patient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1 Strategy Execution IND-enabling Studies Underway for BEAM-301 for Treatment of...

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new...

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

Patient Enrollment into BEACON Phase 1/2 Trial of BEAM-101 On-track for Second Half of 2022 BEAM-201 IND Submitted to FDA; Currently on Clinical Hold BEAM-102 IND Submission and BEAM-301...

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...